Hester Biosciences Limited Q1 Profit Rises 459% on Exceptional Gain

Hester Biosciences Limited reported consolidated net profit of Rs 96.73 crore for the quarter ended June 2026, a 459% year-on-year increase, primarily because of an Rs 85.35 crore exceptional gain from an amendment to the Gates Foundation loan at Hester Africa. Revenue from operations declined 8.2% to Rs 77.24 crore.

What did Hester Biosciences Limited report for Q1 FY27?

Hester Biosciences Limited reported a sharp rise in consolidated profitability for the April-June 2026 quarter, or Q1 FY27, despite lower revenue from operations. Consolidated net profit rose to Rs 96.73 crore from Rs 17.30 crore in Q1 FY26. The reported increase of 459% was driven substantially by a one-time exceptional gain rather than revenue growth.

Revenue from operations stood at Rs 77.24 crore in Q1 FY27, compared with Rs 84.11 crore in the corresponding quarter of the previous year. This represents an 8.2% year-on-year decline. The difference between the movement in revenue and net profit is important because the quarter's bottom-line performance included a material non-operating exceptional item.

Consolidated EBITDA was Rs 111.81 crore, up 105.65% from Rs 26.18 crore in Q1 FY26. EBITDA margin was reported at 145%, compared with 31% a year earlier. The margin exceeding revenue reflects the impact of the exceptional gain included in quarterly profitability.

Why did Hester Biosciences Limited's profit rise so sharply?

The main reason for the increase in reported profit was an Rs 85.35 crore exceptional gain arising from the amendment of the Gates Foundation loan at Hester Africa. Hester Biosciences Limited specifically identified this item as part of consolidated profitability for the June 2026 quarter.

This gain is central to reading the Q1 FY27 numbers. Without separating the exceptional item from the operating result, the reported 459% increase in net profit and 145% EBITDA margin could suggest a level of recurring profitability that is not established by the disclosed revenue figures alone. The company reported lower consolidated revenue from operations during the same period.

The quarter therefore contained two different financial signals. First, the company recorded a large accounting or financing-related exceptional gain linked to Hester Africa. Second, its consolidated operating revenue declined year on year. Both factors need to be considered when comparing Q1 FY27 with Q1 FY26.

How did Q1 FY27 compare with the previous year?

Hester Biosciences Limited's Q1 FY27 profit was substantially higher than the prior-year quarter, while revenue was lower. Net profit increased from Rs 17.30 crore to Rs 96.73 crore, and EBITDA increased from Rs 26.18 crore to Rs 111.81 crore. Revenue from operations fell from Rs 84.11 crore to Rs 77.24 crore.

The company had reported stronger sales growth in the preceding March 2026 quarter. Consolidated March 2026 net sales were reported at Rs 100.11 crore, up 22.2% year on year, while standalone March 2026 net sales were Rs 93.71 crore, up 22.23%. Those figures provide context for the lower revenue reported in the June 2026 quarter.

Earlier quarterly disclosures also showed mixed revenue movement. Consolidated net sales were Rs 77.42 crore in December 2025, up 22.46% year on year, while consolidated September 2025 net sales were Rs 70.97 crore, down 15.2% year on year. The available quarterly data show that sales performance has varied across reporting periods.

What does the exceptional gain mean for investors?

The exceptional gain means that Q1 FY27 reported earnings cannot be assessed solely as a measure of recurring operating performance. Hester Biosciences Limited disclosed that Rs 85.35 crore of the quarter's consolidated profitability arose from the Gates Foundation loan amendment at Hester Africa, making it a major contributor to the Rs 96.73 crore net profit.

For investors, revenue from operations provides an additional reference point because it declined 8.2% year on year. The disclosed results do not provide a separate adjusted profit figure excluding the exceptional gain. As a result, comparisons of quarterly earnings should distinguish between the reported profit and the exceptional item that influenced it.

The June-quarter figures also show why EBITDA margin needs context in this period. At 145%, the reported margin was well above the 31% reported in Q1 FY26 and above the revenue base for the quarter. This outcome is consistent with the stated exceptional gain being included in consolidated profitability.

What business background is relevant to Hester Biosciences Limited?

Hester Biosciences Limited operates in animal health, manufacturing vaccines and health products. The company is described as India's second-largest poultry vaccine maker and supplies an integrated disease-management offering to farmers. Organised poultry farms are reported to have vaccination penetration of roughly 90%.

The company also has a significant presence in PPR vaccine. Hester Biosciences Limited is described as holding approximately 75% of the global PPR vaccine market and as supplying the WOAH vaccine bank and national immunisation programmes. It delivered 6.3 crore PPR vaccine doses under India's PPR programme in Q4 FY26.

Its production network includes a Nepal plant using the Nigerian strain of PPR vaccine for export markets and an India plant using the Sungri strain for domestic programmes. The disclosed arrangement gives the company separate manufacturing bases for export and domestic PPR vaccine requirements.

When will Hester Biosciences Limited provide its next update?

Hester Biosciences Limited scheduled its board meeting for 5 November 2026 to consider unaudited standalone and consolidated financial results for the quarter and six months ended 30 September 2026. The company also scheduled an investor conference call on 5 November 2026 at 2:00 p.m. IST for Q2 and H1 FY27 results.

The scheduled call is set to include Chief Executive Officer and Managing Director Rajiv Gandhi, Executive Director Priya Gandhi, and Chief Financial Officer Ashish Desai. The announcement of the board meeting did not contain financial results or figures. The next disclosed results will provide a further reported reference point after the exceptional gain recorded in Q1 FY27.

Conclusion

Hester Biosciences Limited's Q1 FY27 consolidated net profit rose 459% to Rs 96.73 crore, but the result was heavily shaped by an Rs 85.35 crore exceptional gain linked to the amendment of the Gates Foundation loan at Hester Africa. Revenue from operations fell 8.2% to Rs 77.24 crore, making the distinction between reported earnings and underlying revenue movement particularly relevant.

The next item to watch is the company's Q2 and H1 FY27 financial disclosure for the period ended 30 September 2026. Management's investor call, scheduled for 5 November 2026 at 2:00 p.m. IST, is expected to accompany those results and provide the next company update.